MedTrace Logo

Epigenetic and Genetic Effects in Cancer Patients: Analysis Pre and After Treatment

NCT04200118 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-12-16

No results posted yet for this study

Summary

The prognosis in cancer patients has improved over the years. Survivor rates have increased significantly, and paternity has become an important concern in more than 50% of young male survivors. Sperm cryopreservation before cancer treatment is highly recommendable in these patients, as a strategy to preserve their fertility due to is not possible to predict how the chemo or radiotherapy treatment will affect the spermatogenesis.

The objective of this study is to evaluate if sperm after an antineoplastic treatment can be safely used. To determine the possible effects of oncological treatments in the spermatogenesis, three parameters will be analyzed, aneuploidy frequencies, DNA fragmentation in single and double-strand breaks and methylation levels to determine epigenetic changes before and after the therapy.

If cancer treatment affect sperm genetic integrity, it would have a clinical impact in the offspring of these patients. Identify the different side effects of antineoplastic treatments in DNA sperm will provide a clinical improvement in order to select the best sperm sample in an IVF treatment and it will facilitate genetic counseling

Conditions

  • Male Infertility
  • Cancer
  • Epigenetic Disorder

Interventions

OTHER

Observational

non intervention

Sponsors & Collaborators

  • IVI Barcelona

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2020-04-30
Completion
2021-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200118 on ClinicalTrials.gov